Pulmonary hypertension 2015: current definitions, terminology, and novel treatment options

Clinical Research in Cardiology

Volumn 104, Issue 3, 2015, Pages 197-207

  Rosenkranz, Stephan ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Nice classification; Pulmonary arterial hypertension; Pulmonary hypertension; World symposium

Indexed keywords

AMBRISENTAN; BOSENTAN; ILOPROST; MACITENTAN; PROSTACYCLIN; RIOCIGUAT; SILDENAFIL; TADALAFIL; TREPROSTINIL; ANTIHYPERTENSIVE AGENT;

CHRONIC LUNG DISEASE; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; DISEASE CLASSIFICATION; HEART DISEASE; HUMAN; LUNG EMBOLISM; MULTICENTER STUDY (TOPIC); PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PORTOPULMONARY HYPERTENSION; PROGNOSIS; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STANDARDIZATION; ARTERIAL PRESSURE; CLASSIFICATION; DRUG EFFECTS; HYPERTENSION, PULMONARY; NOMENCLATURE; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PULMONARY ARTERY; RISK FACTOR; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; ARTERIAL PRESSURE; HUMANS; HYPERTENSION, PULMONARY; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PULMONARY ARTERY; RISK FACTORS; TERMINOLOGY AS TOPIC; TREATMENT OUTCOME;

EID: 84925489360     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-014-0765-4     Document Type: Review

References (59)

1. Galiè N, Hoeper MM, Humbert M et al (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung transplantation (ISHLT). Eur Heart J 30:2493–2537
2. Simonneau G, Gatzoulis MA, Adatia I et al (2013) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62(Suppl D):D34–D41
3. Simonneau G, Robbins IM, Beghetti M et al (2009) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54(Suppl S):S43–S54
4. Tuder RM, Archer SL, Dorfmüller P et al (2013) Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol 62(Suppl D):D4–D12
5. Soubrier F, Chung WK, Machado R et al (2013) Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 63(Suppl D):D13–D21
6. McGoon M, Benza RL, Escribano-Subias P et al (2013) Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol 62(Suppl D):D51–D59
7. Rich S, Dantzker DR, Ayres SM et al (1987) Primary pulmonary hypertension: a national prospective study. Ann Intern Med 107:216–223
8. D’Alonzo GE, Barst RJ, Ayres SM et al (1991) Survival in patients with primary pulmonary hypertension. Ann Intern Med 115:343–349
9. Humbert M, Sitbon O, Chaouat A et al (2010) Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 122:156–163
10. Hoeper MM, Huscher D, Ghofrani HA et al (2013) Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol 168:871–880
11. Ryan JJ, Rich JD, Thiruvoipati T et al (2012) Current practice for determining pulmonary capillary wedge pressure predisposes to serious errors in the classification of patients with pulmonary hypertension. Am Heart J 163:589–594
12. LeVarge BL, Pomerantsev E, Channick RN (2014) Reliance on end-expiratory wedge pressure leads to misclassification of pulmonary hypertension. Eur Respir J 43:425 (Epub ahead of print)
13. Hoeper M, Bogaard HJ, Condliffe R et al (2013) Definition and diagnosis of pulmonary hypertension. J Am Coll Cardiol 62(Suppl D):D42–D50
14. Rosenkranz S, Behr J, Ewert R, Ghofrani HA et al (2011) Rechtherzkatheter-Untersuchung bei pulmonaler Hypertonie. Dtsch Med Wochenschr 136:2601–2620
15. Kovacs G, Avian A, Olschewski A, Olschewski H (2013) Zero reference level for right heart catheterization. Eur Respir J 42:1586–1594
16. Barst RJ, Gibbs SR, Ghofrani HA et al (2009) Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 54(Suppl S):S78–S84
17. Galiè N, Corris PA, Frost A et al (2013) Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 62(Suppl D):D60–D72
18. Bolli MH, Boss C, Binkert C et al (2012) The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N′-propyl-sulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist. J Med Chem 55:7849–7861
19. Gatfield J, Mueller Grandjean C, Sasse T, Clozel M, Nayler O (2012) Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS One 7:e47662
20. Iglarz M, Binkert C, Morrison K et al (2008) Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 327:736–745
21. Pulido T, Adzerikho I, Channick RN, For the SERAPHIN Investigators et al (2013) Macitentan and morbidity and mortality in pulmonary arterial hypertension. New Engl J Med 369:809–818
22. Evgenov OV, Pacher P, Schmidt PM et al (2006) NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 5:755–768
23. Ghofrani HA, Hoeper M, Halank M et al (2010) Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension. A phase II study. Eur Respir J 36:792–799
24. Ghofrani HA, Galiè N, Grimminger F, For the PATENT Investigators et al (2013) Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 369:330–340
25. Ghofrani HA, D`Armini AM, Grimminger F, For the CHEST Investigators et al (2013) Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 369:319–329
26. Simonneau G, Lang I, Torbicki A, Hoeper MM, Delcrox M, Karlocai K, Galiè N (2012) Selexipag, an oral, selective IP receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J 40:874–880
27. Actelion press release: selexipag meets primary endpoint in pivotal phase III GRIPHON outcome study in patients with pulmonary arterial hypertension (2014) (Published June 16)
28. Freyhaus T, Dumitrescu D, Berghausen E, Vantler M, Caglayan E, Rosenkranz S (2012) Imatinib mesylate for pulmonary arterial hypertension. Exp Opin Investig Drugs 21:119–134
29. Hoeper MM, Barst RJ, Bourge RC et al (2013) Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 127:1128–1138
30. GlaxoSmithKline/Gilead press release: first-line combination of ambrisentan and tadalafil reduces risk of clinical failure compared to monotherapy in pulmonary arterial hypertension outcomes study (2014) (Published September 8)
31. Galiè N, for the AMBITION Investigators (2014) The AMBITION study: design and results. Presented at ERS International Congress 2014 (abstract #2916)
32. Sitbon O, Jais X, Savale L et al (2014) Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J 43:1691–1697
33. Olsson KM, Delcroix M, Ghofrani HA et al (2014) Anticoagulation and survival in pulmonary arterial hypertension: results from the COMPERA registry. Circulation 129:57–65
34. Rhodes CJ, Howard LS, Busbridge M et al (2011) Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes and mechanistic insights. J Am Coll Cardiol 58:300–309
35. Ruiter G, Lanser IJ, de Man FS et al (2014) Iron deficiency in systemic sclerosis patients with and without pulmonary hypertension. Rheumatology 53:285–292
36. Viethen T, Gerhardt F, Dumitrescu D, Knoop-Busch S, ten Freyhaus H, Rudolph TK, Baldus S, Rosenkranz S (2014) Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deficiency: a pilot study. Int J Cardiol. doi:10.1016/j.ijcard.2014.04.233 (Epub ahead of print)
37. Bursi F, McNallan SM, Redfield MM et al (2012) Pulmonary pressures and death in heart failure. J Am Coll Cardiol 59:222–231
38. Lam CS, Roger VL, Rodeheffer RJ et al (2009) Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 53:1119–1126
39. Ghio S, Gavazzi A, Campana C et al (2001) Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 37:183–188
40. Melenovsky V, Hwang SJ, Lin G, Redfield MM, Borlaug BA (2014) Right heart dysfunction in heart failure with preserved ejection fraction. Eur Heart J [Epub ahead of print]
41. Miller WL, Grill DE, Borlaug BA (2013) Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction. JACC Heart Fail 1:290–299
42. Seiffert M, Sinning JM, Meyer A et al (2014) Development of a risk score for outcome after transcatheter aortic valve implantation. Clin Res Cardiol 103:631–640
43. Zuern CS, Eick C, Rizas K et al (2012) Prognostic value of mild-to-moderate pulmonary hypertension in patients with severe aortic valve stenosis undergoing aortic valve replacement. Clin Res Cardiol 101:81–88
44. Abraham WT, Adamson PB, Bourge RC et al (2011) Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 377:658–666
45. Naejie R, Vachiéry JL, Vanderpool R (2013) The transpulmonary pressure gradient for the diagnoisis of pulmonary vascular disease. Eur Respir J 41:217–223
46. Gerges C, Gerges M, Lang MB et al (2013) Diastolic pulmonary vascular pressure gradient. A predictor of prognosis in out-of-proportion pulmonary hypertension. Chest 143:758–766
47. Rosenkranz S, Bondermann D, Buerke M et al (2011) Pulmonary hypertension due to left heart disease: updated recommendations of the Cologne Consensus Conference 2011. Int J Cardiol 154(Suppl):S34–S44
48. Vachiery JL, Adir Y, Barbera JA et al (2013) Pulmonary hypertension due to left heart diseases. J Am Coll Cardiol 62(Suppl D):D100–D108
49. Guazzi M, Vicenzi M, Arena R, Guazzi MD (2011) Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 124:164–174
50. Dumitrescu D, Seck C, Möhle L, Erdmann E, Rosenkranz S (2012) Therapeutic potential of sildenafil in patients with heart failure and reactive pulmonary hypertension—results of compassionate care treatment. Int J Cardiol 154:205–206
51. Redfield MM, Chen HH, Borlaug BA et al (2013) Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 309:1268–1277
52. Bonderman D, Ghio S, Felix SB, For the LEPHT Investigators et al (2013) Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation 128:502–511
53. Hoeper MM, Andreas S, Bastian A et al (2011) Pulmonary hypertension due to chronic lung disease. Updated recommendations of the cologne consensus conference 2011. Int J Cardiol 154(Suppl):S45–S53
54. Boerrigter BG, Bogaard HJ, Trip P et al (2012) Ventilatory and cardiocirculatory exercise profiles in COPD: the role of pulmonary hypertension. Chest 142:1166–1174
55. Seeger W, Adir Y, Barbera JA et al (2013) Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol 62(Suppl D):D109–D116
56. Mayer E, Jenkins D, Lindner J et al (2011) Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg 141:702–710
57. Kim NH, Delcroix M, Jenkins DP et al (2013) Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol 62(Suppl D):D92–D99
58. Madani MM, Auger WR, Pretorius V et al (2012) Pulmonary endarterectomy: recent changes in a single institution´s experience of more than 2,700 patients. Ann Thorac Surg 94:97–103
59. Sugimura K, Fukumoto Y, Satoh K et al (2012) Percutaneous transluminal pulmonary angioplasty markedly improves pulmonary hemodynamics and long-term prognosis in patients with chronic thromboembolic pulmonary hypertension. Circ J 76:485–488